Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Keros Therapeutics's average diluted shares outstanding for the quarter that ended in Jun. 2026 was 19.80 Mil.
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Be Aware
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Keros Therapeutics Shares Outstanding (Diluted Average) Related Terms
Keros Therapeutics Shares Outstanding (Diluted Average) Historical Data
* Premium members only.
The historical data trend for Keros Therapeutics's Shares Outstanding (Diluted Average) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
What does a Shares Outstanding (Diluted Average) of 19.80 Mil mean?
Keros Therapeutics (KROS) has a Shares Outstanding (Diluted Average) of 19.80 Mil as of Jun. 2026. The average shares outstanding over two periods including dilutive securities like preferred shares and convertibles. View historical data on Keros Therapeutics and its competitors.
Is Keros Therapeutics' Shares Outstanding (Diluted Average) too high?
Keros Therapeutics' current Shares Outstanding (Diluted Average) is 19.80 Mil. Overall, Keros Therapeutics has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Keros Therapeutics' Shares Outstanding (Diluted Average) compare to RNA and NBP?
Keros Therapeutics' Shares Outstanding (Diluted Average) of 19.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Diluted Average) for a Biotechnology company?
A good Shares Outstanding (Diluted Average) depends on the Biotechnology industry context. However, Shares Outstanding (Diluted Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Diluted Average) mean?
A high Shares Outstanding (Diluted Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods including dilutive securities like preferred shares and convertibles. View historical data on Keros Therapeutics and its competitors. Keros Therapeutics's current Shares Outstanding (Diluted Average) is 19.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keros Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Keros Therapeutics (KROS) is currently considered Fairly Valued. The stock's GF Value™ is $10.09, compared to a current price of $10.09 — trading right at its estimated fair value. The current Shares Outstanding (Diluted Average) is 19.80 Mil. Keros Therapeutics' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Diluted Average) calculated?
Shares Outstanding (Diluted Average) is calculated from a company's financial statements. For Keros Therapeutics (KROS), the current Shares Outstanding (Diluted Average) is 19.80 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keros Therapeutics (KROS) Overvalued in 2026?
Based on GuruFocus' analysis, Keros Therapeutics stock appears to be undervalued.
The current stock price of $10.09 is trading 0% below its estimated GF Value™ of $10.09.
GuruFocus considers Keros Therapeutics to be Fairly Valued.
Key valuation signals for KROS:
Shares Outstanding (Diluted Average): 19.80 Mil
GF Value™: $10.09 vs. price of $10.09 (0% below fair value)
No single metric tells the full story. See the KROS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
52GF Score
Get the complete analysis for KROS
Shares Outstanding (Diluted Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KROS has been successfully added to your 
